ALK and non-small cell lung carcinoma: Entrectinib, a ROS1, ALK, and TRK inhibitor, was approved by the FDA in 2019 for advanced ROS1+ NSCLC.39 An integrated analysis of ALKA-372-001, STARTRK-1, and STARTRK-2 trials demonstrated an ORR of 68%, mPFS of 15.7 months and mOS of 47.8 months.5 The most frequent entrectinib-associated AEs include dysgeusia, dizziness, and constipation.